DXCM INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of DexCom, Inc.

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].